|
Video: What is a Stock Split?
|
|
Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapies. Co. focuses on therapeutics for the treatment of diseases with few or no approved therapies. Co.'s main programs are in rare forms of chronic kidney disease (CKD) and a rare neurological disease. Co.'s primary product candidates include bardoxolone methyl (bardoxolone) in patients with CKD caused by Alport syndrome and omaveloxolone in patients with a neurological disorder called Friedreich's ataxia. Both bardoxolone and omaveloxolone activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. According to our RETA stock split history records, RETA has had 0 splits. | |
|
RETA (RETA) has 0 splits in our RETA stock split history database.
Looking at the RETA stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into RETA shares, starting with a $10,000 purchase of RETA, presented on a split-history-adjusted basis factoring in the complete RETA stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/27/2016 |
|
End date: |
09/26/2023 |
|
Start price/share: |
$14.28 |
|
End price/share: |
$172.36 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
1,107.00% |
|
Average Annual Total Return: |
40.42% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$120,693.62 |
|
Years: |
7.34 |
|
|
|
|
|